{"id":"ovarian-function-suppression-aromatase-inhibitor","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Vaginal dryness"},{"rate":null,"effect":"Arthralgia/myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Mood changes/depression"},{"rate":null,"effect":"Bone loss/osteoporosis"}]},"_chembl":{"chemblId":"CHEMBL5715921","moleculeType":null,"molecularWeight":"652.58"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Ovarian function suppression (OFS) agents such as GnRH agonists or antagonists shut down the ovaries' production of estrogen in premenopausal women. Aromatase inhibitors (AIs) block the enzyme aromatase, which converts androgens to estrogen in peripheral tissues. Together, this dual approach maximizes estrogen deprivation in hormone receptor-positive breast cancer by eliminating both ovarian and peripheral sources of estrogen.","oneSentence":"This combination suppresses ovarian estrogen production while blocking the conversion of androgens to estrogen, reducing total circulating estrogen in premenopausal women with hormone receptor-positive breast cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:00.052Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative breast cancer in premenopausal women (adjuvant or metastatic setting)"}]},"trialDetails":[{"nctId":"NCT05879926","phase":"PHASE3","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-08-31","conditions":"Breast Cancer","enrollment":3960},{"nctId":"NCT07213206","phase":"PHASE3","title":"CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-10-07","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT07190443","phase":"PHASE3","title":"Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)","status":"RECRUITING","sponsor":"Japanese Foundation for Cancer Research","startDate":"2025-02-07","conditions":"Breast Cancer, Locoregional Recurrence, Abemaciclib","enrollment":290},{"nctId":"NCT04352777","phase":"PHASE2","title":"Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer","status":"COMPLETED","sponsor":"Duke University","startDate":"2020-09-14","conditions":"Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor","enrollment":18},{"nctId":"NCT05333328","phase":"PHASE4","title":"OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk","status":"RECRUITING","sponsor":"Gangnam Severance Hospital","startDate":"2023-02-06","conditions":"Breast Cancer, Estrogen Receptor Positive Tumor, HER2-negative Breast Cancer","enrollment":418},{"nctId":"NCT06606535","phase":"","title":"ENDO-BRAIN: Effects of Endocrine Adjuvant Therapy with Aromatase Inhibitors on the Cognitive Function of Breast Cancer Patients","status":"RECRUITING","sponsor":"Ospedale Policlinico San Martino","startDate":"2024-06-13","conditions":"Cognitive Side Effects of Cancer Therapy, Hypoestrogenism","enrollment":60},{"nctId":"NCT05891093","phase":"PHASE3","title":"Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"Breast Cancer","enrollment":766},{"nctId":"NCT05870813","phase":"","title":"CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer","status":"UNKNOWN","sponsor":"Institut fuer Frauengesundheit","startDate":"2023-03-10","conditions":"Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma","enrollment":3000},{"nctId":"NCT05801705","phase":"","title":"Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-06-01","conditions":"Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer, Breast Cancer Patients at Intermediate to High Risk","enrollment":700},{"nctId":"NCT02914158","phase":"PHASE3","title":"Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-03-30","conditions":"Breast Cancer","enrollment":680},{"nctId":"NCT02440230","phase":"PHASE2","title":"Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2015-05","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT02917005","phase":"PHASE2","title":"PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer","status":"UNKNOWN","sponsor":"Hamdy A. Azim","startDate":"2019-05-07","conditions":"Metastatic Breast Cancer","enrollment":160},{"nctId":"NCT04476485","phase":"","title":"Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy","status":"RECRUITING","sponsor":"Shengjing Hospital","startDate":"2021-07-19","conditions":"Breast Cancer","enrollment":1000},{"nctId":"NCT02532400","phase":"PHASE3","title":"Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients","status":"TERMINATED","sponsor":"Ruijin Hospital","startDate":"2016-03","conditions":"Breast Cancer","enrollment":21},{"nctId":"NCT03750396","phase":"PHASE2","title":"Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Gangnam Severance Hospital","startDate":"2018-08-01","conditions":"Breast Cancer, Recurrent Breast Cancer, Stereotactic Body Radiotherapy","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":182,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ovarian Function Suppression + Aromatase Inhibitor","genericName":"Ovarian Function Suppression + Aromatase Inhibitor","companyName":"NRG Oncology","companyId":"nrg-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination suppresses ovarian estrogen production while blocking the conversion of androgens to estrogen, reducing total circulating estrogen in premenopausal women with hormone receptor-positive breast cancer. Used for Hormone receptor-positive, HER2-negative breast cancer in premenopausal women (adjuvant or metastatic setting).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}